Horizant Articles
GlaxoSmithKline gives up on XenoPort Horizant collaboration
9 November 2012
FDA clears GlaxoSmithKline's Horizant for PHN
8 June 2012
Backing for Japanese approval of Regnite, Ranmark and Cancidas
5 December 2011
FDA filings for Ironwood and Forest for linaclotide, and GSK and XenoPort for Horizant ER
10 August 2011
GlaxoSmithKline and XenoPort respond to FDA on Horizant for RLS; Pozen gets positive advisory recommendation on GI drug
8 November 2010
EPO Rules European Patent for XenoPort’s XP13512 is valid; Almirall grants Eisai marketing rights to cinitapride in China
16 April 2010
Showing 1-8 of 8 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
